A 2026 meta-analysis of 7 randomized trials confirms intradiscal MSC injections reduce chronic back pain and disability significantly. Meanwhile, bioengineered exosome therapies are redefining what cell-free disc regeneration looks like.
CRISPR-edited MSCs, iPSC-derived cells, combinatorial cell therapy, and exosome-based approaches are transforming PAD/CLI treatment. Six landmark 2026 papers and five active clinical trials reviewed for clinicians and researchers.
Pulmonary arterial hypertension kills half its patients within five years. 2026 research shows mesenchymal stem cells — especially HO-1-modified and mitochondria-primed MSCs — are reversing the vascular remodeling at the disease’s core. Here’s the science behind the breakthrough.
A 2026 Phase 1 trial showed that MSC-derived exosomes injected into the ear were safe and improved hearing in patients with sudden sensorineural hearing loss. Here’s what the breakthrough means and when it could be available.
Stem cell therapy prices range from $2,000 to $100,000 depending on where you go. Here’s what actually drives the cost, what’s included, and how Thailand compares to the US, Australia, and Europe in 2026.
MSC therapy is offering new hope for IBD patients who don’t respond to conventional biologics. Here’s what the 2026 clinical data shows.
Kaempferol-modified MSC extracellular vesicles suppress ADAM10 and restore UV-damaged collagen. This is the future of anti-aging skin repair.
A 2025 clinical trial reports the first-ever strength improvement in ALS patients using intranasally delivered MSC exosomes — zero adverse events across 32 treatments.
PRP has its limits. For serious tendon and ligament injuries, stem cells are showing results PRP cannot match.
A June 2026 study shows that senolytic preconditioning dramatically improves MSC efficacy by removing the SASP factors that suppress tissue repair. Plus: AAT-MSCs reverse diabetes via immune reprogramming, and a phase III MSC trial for meniscal repair reaches completion.
French 
English 
Chinese 
Russian